Navigation Links
RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
Date:12/12/2008

ents had stable disease and two patients had progressive disease. The critical dose-limiting toxicities (i.e., dose-limiting toxicities in cycle 1) occurring in the 5 mg daily treatment group included grade 3/4 neutropenia, grade 3 stomatitis, grade 3 fatigue and grade 3 anorexia. In the 30 mg weekly treatment group, grade 3/4 neutropenia was the only critical dose-limiting toxicity. There were no critical dose-limiting toxicities in the 20 mg weekly RAD001 treatment arm. The most commonly reported grade 3/4 adverse events (greater than or equal to 10%) suspected of being related to study treatment were neutropenia, stomatitis and leukopenia.

About breast cancer

In the US, invasive breast cancer affects one in eight women. It is the second most common cancer among women in the US and the second leading cause of cancer-related death in women. Breast cancer is expected to claim the lives of approximately 40,500 women in 2008.

Inside a breast there are many lobes, ducts and vessels that support several important functions in the body, including reproductive needs and fighting infection. In breast cancer, some of the cells in the breast begin growing abnormally and divide more rapidly than healthy cells. The quick division of cells may cause spreading through the breast, to the lymph nodes or to other parts of the body.

About RAD001

RAD001, an oral once-daily inhibitor of mTOR, is an investigational drug being studied in multiple tumor types. In cancer cells, RAD001 provides continuous inhibition of mTOR, a protein that acts as a central regulator of tumor cell division, cell metabolism and blood vessel growth.

The safety and efficacy profile of RAD001 has not yet been established in oncology and there is no guarantee that RAD001 will become commercially available for oncology indications. The active ingredient in RAD001 is everolimus. The active ingredient everol
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer
2. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
3. RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
4. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
5. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
6. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
7. New Study Shows PCR and FCR Have Significant Activity in B-cell Chronic Lymphocytic Leukemia
8. Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful
9. Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows
10. Third Pivotal Phase 3 Study for NicOx Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results
11. Soft Contact Lenses Do Not Lead to Myopic Creep in Children, Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hcb7bz/pharmaceutical ) has ... (London, UK - November 16-18, 2015)" conference to their offering. ... including Columbia, Peru , Brazil ... Uruguay , Paraguay , ... , Chile This seminar can ...
(Date:9/2/2015)... -- Seeger Weiss LLP is reporting that Zimmer Holdings Inc.,s ... 2015. Since the product was approved ... NexGen knee implant surpassed FDA investigation and mandatory product ... that the product is substantially similar to a preexisting ... In 2001, Zimmer began distributing High ...
(Date:9/2/2015)... , Sept. 2, 2015 Research and ... of the "Medical Device Studies: Clinical Evidence ... to their offering. This course ... involved in gathering clinical evidence required for medical ... required for all medical devices and the emphasis ...
Breaking Medicine Technology:Pharmaceutical Regulatory Affairs in Latin America Seminar - London, UK - November 16-18, 2015 2Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2Medical Device Studies: Clinical Evidence Course - London, UK - November 10-11, 2015 2
... Potential New Approach for the Treatment of Inflammatory ... ... Million Payment from Partner GlaxoSmithKline, MOUNTAIN VIEW, Calif., May 13 ... trial of CCX354, an,orally-available, novel small molecule compound designed to specifically,target ...
... FRANCISCO, Calif., May 12 Napo,Pharmaceuticals, Inc., (LSE: ... in collaboration with QualityMetric, Inc. describing the development,of ... Health-Related,Quality of Life (HR-QoL) aspects of chronic diarrhea ... Society for Pharmacoeconomics and,Outcomes Research (ISPOR) Annual Meeting ...
Cached Medicine Technology:ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 2ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 3ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 4ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 5Napo Presents at ISPOR Meeting in Toronto 2
(Date:9/3/2015)... ... ... Mum n Me is pleased to announce the launch of its ... maximum protection from sun exposure, wind, bugs, and germs. The Mum n Me Baby ... keeping the cover securely in place. The new car seat cover is made with ...
(Date:9/3/2015)... ... September 03, 2015 , ... When looking at the types of people who have ... of two categories: those that have a weak appetite or those that have a fast ... to gain weight, CB-1 Weight Gainer gives three tips for slowing down metabolism. , The ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... announced that Bob Anders and Kelley Chapman will be joining the company’s executive ... , Anders has over 30 years’ experience in healthcare product and project ...
(Date:9/2/2015)... Basalt, Colorado (PRWEB) , ... September 03, 2015 , ... ... to its wellness services - two retreats geared towards kick-starting and inspiring wellness in ... "We love being a part of developing a whole mind-body approach to fitness - ...
(Date:9/2/2015)... ... September 03, 2015 , ... Each year, the editors of ... servants, activists, corporate executives, entrepreneurs, health care professionals, and others have had the ... the magazine to tap the National League for Nursing’s outspoken CEO, Beverly ...
Breaking Medicine News(10 mins):Health News:Mum n Me Announces New Baby Car Seat Cover 2Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 2Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 3Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 2Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 3Health News:TAC Introduces New Retreats for Fall Fitness 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3
... lawyers' access to a high-profile detainee at Guantanamo Bay, ... security secrets" whose revelation could "cause extremely grave damage", ... prisoners at secret CIA prisons must not be allowed ... - even to their lawyers, the Post reported.,A lawyer ...
... Researchers want doctors to be ready to handle medical problems ... it. //In the present state, what happens when a person ... get back to normal conditions for treatment in time simply ... findings from a UF study show there is little difference ...
... the trans-fat controversy for quite a while, has decided to ... oils! This is perhaps the last nail in the coffin! ... have already communicated their intention of banishing trans fats from ... Government to bring in a law that would entail manufacturers ...
... leading economic think tank has urged policymakers to ensure ... women to reduce their// economic and social vulnerability., ... disproportionately affected by HIV and AIDS get equal opportunities ... Economic Research (NCAER) in a report on 'Gender impact ...
... against time to prevent HIV, the virus that causes AIDS, ... in// the number of prostitutes and lack of safe sex ... three-year programme to encourage the use of condoms and voluntary ... UNAIDS estimates 500 HIV-infected people in Bhutan, a country of ...
... battled off the infection appear to be shielded from ... Canadian study.// ,WebMD.com said that Drug users ... British Columbia researchers for presence of Hepatitis C antibodies ... C mainly through their habit of sharing needles during ...
Cached Medicine News:Health News:Researchers explore medicine in space 2Health News:Researchers explore medicine in space 3Health News:Equal Opportunities For HIV-Positive Women Urged 2Health News:HIV/AIDS Epidemic Scare In Bhutan 2
... Solution For Your Tracheostomy Care Needs, ... features the latest components for efficient and ... task. Designed by clinicians, these latex-free trays ... patient and caregiver. All of our trays ...
... Medline Has the Right Solution For ... tracheostomy clean and care tray features the ... of this important infection control task. Designed ... the individual needs of each patient and ...
... and alternate care facilities with a ... which offer the finest in nursing ... the guidance of experienced nursing personnel, ... what is required for efficient and ...
... and alternate care facilities with a ... which offer the finest in nursing ... the guidance of experienced nursing personnel, ... what is required for efficient and ...
Medicine Products: